IMRICOR LAUNCHES U.S. COMMERCIAL OPERATIONS

RADY CHILDREN'S HOSPITAL-SAN DIEGO TO BECOME FIRST U.S. CUSTOMER

Key Highlights

- Rady Children's Hospital–San Diego is purchasing Imricor's NorthStar® iMR mapping and guidance system, becoming the **first commercial U.S. hospital customer** and marking the commencement of Imricor's U.S. commercial launch
- Follows U.S. FDA 510(k) clearances of NorthStar and the Vision-MR® Diagnostic Catheter, as well as the subsequent pediatric label expansions clearing both products for **patients of all ages**
- **Rady Children's** will lead the way in radiation-free care launching a NorthStar-guided iMR **cardiac catheterisation** program, with the intention to expand into radiation-free electrophysiology and ablation procedures as soon as possible
- **Marks the launch of *Imricor Cardiovascular*,** a vertical that opens an entirely new market for Imricor alongside its electrophysiology and ablation business. Harnessing the superior imaging power of MR for cardiac catheterisation enables Imricor to serve more than **250 children's hospitals** and more than **2,000 adult hospitals** across the United States
- Several additional U.S. hospitals are in the **final stages of the purchasing process**, and sales at these sites are expected over the coming weeks
- Revenue from these NorthStar sales is expected to exceed the aggregate full year revenue from the European business in 2025
- U.S. commercial team expanding with an additional **U.S. Capital Sales Manager** to cover the southeast region of the U.S., as well as further hires planned for the sales organisation over the coming months
- Cardiac catheterisation in an iMR lab delivers **compelling hospital economics**: a **single-session workflow** replacing separate imaging and X-ray cath lab sessions, per-patient procedural time savings of approximately 35%, meaningful per-patient cost savings, and unlocking existing X-ray cath lab capacity for other interventional procedures that can add significant additional revenue for the hospital

27 July 2026 – Melbourne, Australia (**26 July 2026** – Minneapolis, MN United States) – **Imricor Medical Systems, Inc.** (**Company** or **Imricor**) (**ASX: IMR**) is pleased to announce the commencement of its official U.S. commercial launch. Rady Children's Hospital – San Diego (Rady Children's) will become the first U.S. customer, with the purchase of Imricor's NorthStar interventional magnetic resonance (iMR) mapping and guidance system. Rady Children's is home to one of the leading pediatric cardiology programs in the United States and will be the first U.S. hospital to commit to delivering cardiac catheterisation procedures guided by NorthStar in a 100% radiation-free iMR setting.

“This new [NorthStar] software and clinical application for pediatric patients is part of the vision we had when we first built the Dickinson Image Guided Intervention Center. We are excited to be the first pediatric site."

Chris Abe
Associate Chief Operating Officer
Rady Children’s Hospital

Today’s announcement follows a rapid sequence of U.S. regulatory milestones. In January 2026, Imricor received FDA 510(k) clearances for the Vision-MR Diagnostic Catheter, the Company’s first U.S. clearance, and for NorthStar, the world’s first and only iMR 3D mapping and guidance system. In July 2026, the FDA cleared pediatric label expansions for both products, permitting their use in patients of any age and opening the door to the more than 250 children’s hospitals across the United States.

Imricor Cardiovascular – A New Vertical

With this foundation in place, Imricor is launching **Imricor Cardiovascular,** a vertical offering that harnesses the power of magnetic resonance to help physicians perform cardiac catheterisation procedures under real-time MR guidance using NorthStar. Imricor Cardiovascular opens **an entirely new market for the Company** alongside its electrophysiology business, and the Company expects to continue adding devices and applications within the Cardiovascular business over time. Because NorthStar and the Vision-MR Diagnostic Catheter are cleared for patients of all ages, Imricor can now serve more than 250 children’s hospitals in the United States and more than 2,000 adult hospitals performing cardiac catheterisation procedures nationwide.

For patients, and especially for children born with congenital heart defects who may require repeated catheterisations from the earliest years of life, the benefits are profound. MR guidance eliminates procedure-related exposure to ionising X-ray radiation, to which younger patients are particularly sensitive, while providing superior soft tissue visualisation and richer functional data, such as blood flow or cardiac output, than X-ray fluoroscopy can offer.

"Children born with congenital heart disease often require repeated cardiac catheterizations across their lifetime to measure hemodynamics or treat underlying defects. These procedures have historically been guided by X-ray fluoroscopy, which exposes children to ionising radiation, at a time when they are growing and are particularly susceptible to radiation exposure. MR guidance eliminates exposure to ionising radiation for both patients and staff, while providing us with improved soft tissue differentiation and functional information that fluoroscopy can’t provide. We're proud that Rady Children's Health is the first pediatric center in the world to bring this new technology to our patients."
- **Dr. Brent Gordon, Interventional Cardiologist, Rady Children’s Hospital**

The clinical case is matched by a powerful economic one. In the traditional workflow, a patient may require an MRI scan and a separate X-ray lab catheterisation. Two sessions, on two different days, each with its own complete clinical team. In the interventional MR (iMR) lab, these are combined into a single session with a single team, delivering per-patient procedural time savings of approximately 35% and material reductions in per-patient operational costs. Moving routine cardiac catheterisations into the iMR lab also frees X-ray cath lab capacity for other interventional procedures, compounding the economic value that an iMR program delivers to hospital systems. Imricor's technology is designed not only to make procedures better and safer for patients, but to help hospitals be more efficient and more productive in delivering them.

For Rady Children's, cardiac catheterisation is the beginning, not the end. The hospital's intention is to offer patients a fully radiation-free pathway across cardiac catheterisation, diagnostic electrophysiology, and cardiac ablation.

"What excites me most is what MR guidance lets us see — anatomy, function, and flow, in real time. Questions that used to require separate studies on separate days can be answered in a single session, which means fewer anesthetics for our patients, less disruption for families, and better use of the hospital's resources. This is the direction our field has been waiting to move in, and Rady Children's is leading it."
- **Dr Alejandro Borquez, Pediatric and Congenital Electrophysiologist, Rady Children's Hospital**

Commercial momentum is building beyond San Diego. Several additional U.S. hospitals are in the final stages of their purchasing processes and are expected to purchase NorthStar over the coming weeks. With this momentum, the Company is scaling its sales organisation by adding an additional U.S. Capital Sales Manager for the southeast region of the United States, along with additional sales reps and internal sales operations personnel to support the growth over the coming months.

Imricor's Chair and CEO, Steve Wedan, reflected on this historic moment: "Twenty years ago, I sat alone in my basement and wrote a business plan aiming to start a company that would finally (after so many had tried and failed) enable interventional magnetic resonance procedures. My plan was to reinvent every device and system used in an interventional procedure, and make them compatible with magnetic resonance, because MR is the gold standard in advanced imaging. Then I planned to build a world-class team to develop, manufacture, gain approvals, and sell this platform of devices all over the world.

"I believed then, as I believe now, that interventional medicine needs better imaging to advance the field for the benefit of patients. I also hold the conviction that radiation exposure, a byproduct of an antiquated X-ray imaging modality, is unnecessary when delivering better imaging to interventions.

"This journey has taken me and this company all over the world, and it is remarkably satisfying for me personally, to now launch this platform technology at home. It is particularly meaningful to me that the first patients in the U.S. to benefit from our products (outside of clinical trials) are children, perhaps the most vulnerable patients when it comes to radiation exposure.

"Maybe I didn't know what I was getting myself into twenty years ago in my basement, and maybe the business plan I drafted was too ambitious. But it's done now, and I am extremely pleased with the result and the world-class team that we built to make Imricor real. The best part is, the plan keeps growing, and the new applications are all around us. This is just the beginning."

ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO

Media and Investor Relations Contacts:

Simon Hinsley
Executive Director, NWR
simon@nwrcommunications.com.au
+61 401 909 653

Nick Corkill
VP Corporate Strategy, Imricor
nick.corkill@imricor.com
+61 450 475 633

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional medical procedures better, safer, and more cost effective by making it possible for these procedures to be performed under real-time magnetic resonance (MR) guidance, rather than under x-ray fluoroscopy guidance, thus taking advantage of MR's superior imaging capabilities.

Imricor's Products

Imricor is a pioneer and world leader in developing MR-compatible products for interventional MR (iMR) procedures. The Company's products include capital equipment, such as the NorthStar® Mapping System and the Advantage-MR® EP Recorder/Stimulator. Single-use devices include a variety of ablation catheters, diagnostic catheters, steerable sheaths, and other tools used in an iMR lab

Imricor's products are approved in the European Union, the Kingdom of Saudi Arabia, and New Zealand. NorthStar is cleared in the US.

Foreign Ownership Restrictions

Imricor's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons excluding qualified institutional buyers (QIBs, as defined in Rule 144A under the Securities Act). However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU. sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.